Mallinckrodt (NYSE:MNK) is scheduled to announce its earnings results before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of $1.69 per share for the quarter.
Mallinckrodt (NYSE MNK) opened at $16.16 on Friday. Mallinckrodt has a 12-month low of $15.27 and a 12-month high of $54.90. The stock has a market cap of $1,512.48, a P/E ratio of 4.37, a PEG ratio of 0.30 and a beta of 1.04. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38.
In other Mallinckrodt news, Director Dr Kneeland Youngblood purchased 4,560 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The stock was acquired at an average cost of $21.94 per share, with a total value of $100,046.40. Following the completion of the purchase, the director now directly owns 19,789 shares in the company, valued at approximately $434,170.66. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.77% of the company’s stock.
A number of equities analysts have recently issued reports on MNK shares. Canaccord Genuity reduced their target price on shares of Mallinckrodt from $38.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Stifel Nicolaus reduced their target price on shares of Mallinckrodt from $70.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Jefferies Group started coverage on shares of Mallinckrodt in a research report on Wednesday, November 8th. They set a “buy” rating and a $30.00 target price on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $52.00 target price on shares of Mallinckrodt in a research report on Thursday, November 2nd. Finally, Morgan Stanley reduced their target price on shares of Mallinckrodt from $40.00 to $27.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. Mallinckrodt has an average rating of “Hold” and a consensus price target of $42.64.
TRADEMARK VIOLATION NOTICE: This article was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://transcriptdaily.com/2018/02/25/mallinckrodt-mnk-scheduled-to-post-quarterly-earnings-on-tuesday.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.